Fig. 3From: Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST studya Overall LS mean change from month 1 to 3 in monthly migraine headache days; b LS mean change at month 1 to 3 in monthly migraine headache daysLS, least squares; SE, standard error. ***p < 0.0001 versus placeboBack to article page